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Abstract
Background: Pancreatic cancer cells generate metastases because they can survive the stress imposed by the new
environment of the host tissue. To mimic this process, pancreatic cancer cells which are not stressed in standard culture
conditions are injected into nude mice. Because they develop xenografts, they should have developed adequate stress
response. Characterizing that response might provide new strategies to interfere with pancreatic cancer metastasis.
Methodology/Principal Findings: In the human pancreatic cancer cell lines Panc-1, Mia-PaCa2, Capan-1, Capan-2 and
BxPC3, we used Affymetrix DNA microarrays to compare the expressions of 22.000 genes in vitro and in the corresponding
xenografts. We identified 228 genes overexpressed in xenografts and characterized the implication of one of them, WSB1, in
the control of apoptosis and cell proliferation. WSB1 generates 3 alternatively spliced transcripts encoding distinct protein
isoforms. In xenografts and in human pancreatic tumors, global expression of WSB1 mRNA is modestly increased whereas
isoform 3 is strongly overexpressed and isoforms 1 and 2 are down-regulated. Treating Mia-PaCa2 cells with stress-inducing
agents induced similar changes. Whereas retrovirus-forced expression of WSB1 isoforms 1 and 2 promoted cell growth and
sensitized the cells to gemcitabine- and doxorubicin-induced apoptosis, WSB1 isoform 3 expression reduced cell
proliferation and enhanced resistance to apoptosis, showing that stress-induced modulation of WSB1 alternative splicing
increases resistance to apoptosis of pancreatic cancer cells.
Conclusions/Significance: Data on WSB1 regulation support the hypothesis that activation of stress-response mechanisms
helps cancer cells establishing metastases and suggest relevance to cancer development of other genes overexpressed in
xenografts.
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Introduction
Pancreatic cancer is a highly lethal disease with a poor long-term
survival rate for patients with locally advanced and metastatic
stages[1–3].Major reasonsforthis poor outcomeareourinabilityto
diagnose pancreatic cancer at an early stage because of the lack of
specific symptoms, location of the pancreas deep into the peritoneal
cavity and early occurrence of metastases. Therefore, in the
majority of patients, by the time of diagnosis, regional lymph node
and liver metastasis of pancreatic cancer has occurred, limiting the
effectiveness of the only known curative options which must include
surgical resection[4–6]. To date, radiotherapy or chemotherapy
have not resulted in significant improvement in long-term
survival[7]. The causes of pancreatic cancer are not yet precisely
understood. Many gene products show deregulated functions.
Numerous growth factors and their receptors are overexpressed
during the progression of pancreatic cancer[7–9] but these findings
have hardly led to any improvement in pancreatic cancer therapy.
Our strategy to identify new potential targets for pancreatic
cancer therapy is based on the idea that tumoral progression is
always accompanied by changes in the microenvironment and that
its success depends on the ability of cancer cells to adapt to this
new microenvironment. In fact, it is known that cancer
progression involves several successive steps. Within the primary
tumor, cells are first selected on the basis of rapid growth, low
response to apoptotic signals and a capacity to escape the host
immune system. These cells leave the primary tumor and migrate
through the organism. However, not all of them will generate
metastases in all tissues. That process is selective and depends both
on the capacity of tumor cells at establishing interactions with the
host tissue and on their capacity at managing the environmental
factors to which they are exposed in their new location. The
phenotype of the tumor cell is adapted to its original environment,
the environment of the organ in which the primary tumor
developed. Since the environment provided by the target organ is
different from the original one, it will put the invading tumor cell
under microenvironmental stress pressure. As a consequence, the
ability of the tumor cell to resist that stress could be determinant in
the success of metastasis development. The cell will activate its
defence program in order to survive and, if successful, proliferate.
PLoS ONE | www.plosone.org 1 June 2008 | Volume 3 | Issue 6 | e2475Our goal was to identify the genes involved in this program
because inhibition of their expression might be a new way of
targeting pancreatic cancer. In this paper we describe a panel of
potential pancreatic cancer genes selected using a xenograft
strategy and analyze the structure and function of one of them, the
WSB1 gene, in relation to pancreatic tumor progression.
Results
The panel of pancreatic cancer stress genes
The model we chose to establish the panel of potential
pancreatic progression-related genes is the following: We used 5
human pancreatic cancer cell lines with different genetic
backgrounds, Panc-1, Mia-PaCa2, Capan-1, Capan-2 and
BxPC3. We made the hypothesis that, in standard culture
conditions, these cells are not stressed by their microenvironment.
Upon injection into the nude mouse, they will be exposed to the
stress of a different environment the xenograft mimicking
metastasis. Although the xenograft model reflects only partly what
really happens with metastasis, it is a good means to put cells in an
environment quite different from their usual environment. As a
consequence an important stress will be generated, to which the
cells will have to resist. In each cell line, we compared the
expressions of 22.000 genes in vitro and in the xenografts, using
the Affymetrix microarray approach. To ensure that selected
genes are representative of a large proportion of human pancreatic
tumors, only genes whose expression was modified at least twofold
in all 5 tumors were considered. Under these conditions, we could
select 228 genes overexpressed in tumors and 13 which were
down-regulated. The full data are accessible online at http://
www.inserm-u624.univ-mrs.fr/affymetrix/. Several among the
most overexpressed genes are poorly characterized if not totally
unexplored. As a first step, we chose to focus on WSB1 (WD-
repeat and SOCS Box containing-1) because, as described
hereunder, it showed the original feature of generating, by
alternative splicing, 3 variant transcripts encoding distinct protein
isoforms, whose regulation in xenografts and upon exposure to
several stresses is not coordinated.
WSB1 expression in pancreatic tumor xenografts
The complete protein generated by transcript variant 1, isoform
1, is composed of 3 domains (an N-terminal domain, a protein-
protein interaction domain comprising 8 WD-repeats, and a SOCS
box) (Figure 1).Isoform2 lacksalmostthe entire N-terminal domain
and the first WD-repeat. Finally, a premature stop codon in isoform
3 generates a truncated protein lacking the C-terminal part of the
protein, corresponding to 6 WD-repeats and the SOCS box.
If global expression of the gene, detected by the 213406_at
Affymetrix probe corresponding to the transcription of all three
isoforms, is only increased 1.17 to 2.38 fold in mouse xenografts
depending of the cell line, the expression of isoform 3, detected by
the 201295_s_at Affymetrix probe, is increased 4.63 to 20.32 fold
(Table 1). These results were controlled by quantitative RT-PCR
analysis. We developed Homo sapiens-specific primers to analyze
independently the expressions of WSB1 isoform 3, isoforms 1+2
and isoforms 1+2+3 (global expression) (Figure S1). We found that
global expression of WSB1 was increased by 1.75 to 3.93 fold in
tumors (data not shown). Interestingly, expression of isoform 3 was
increased by 3.7 to 9 fold whereas that of isoforms 2+3 was
decreased by 5 to 20% (Figure 2), in agreement with DNA chip
data. Therefore, rather than an increase in WSB1 global
expression in xenografts tumors, compared to cells maintained
in vitro, we observed a significant shift in alternative splicing in
favor of isoform 3 which becomes largely predominant in tumors.
To check the clinical relevance of these findings, we measured
the expression of the WSB1 isoforms by quantitative RT-PCR in 8
human pancreatic adenocarcinoma samples. We observed in these
Figure 1. The three proteic isoforms of wsb1 and their
subcellular localization. A. Schematic representation of WSB1
isoforms 1, 2 and 3. B. WSB1 isoforms were expressed as EGFP or V5
tag fusion proteins and subcellular localization was analyzed by direct
fluorescence of after immunocytochemistry using EGFP or V5 antibod-
ies respectively.
doi:10.1371/journal.pone.0002475.g001
Table 1. Microarray signal intensities recorded for WSB1
(arbitrary units)
In vitro Xenografts ratio
201295_s_at
Isoform 3
BxPC3 77.8 790.9 10.2
Panc-1 114.9 532.0 4.6
Capan-1 66.8 529.9 7.9
Capan-2 33.9 688.9 20.3
Mia-Paca2 75.0 407.6 5.4
213406_at
Isoforms 1+2+3
BxPC3 97.7 158.6 1.6
Panc-1 117.8 230.1 1.9
Capan-1 109.2 144.2 1.3
Capan-2 55.2 131.6 2.4
Mia-Paca2 124.2 145.4 1.2
doi:10.1371/journal.pone.0002475.t001
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low level of isoforms 1+2 (Figure 2). This suggests that the
expression profile of WSB1 observed in mice xenografts is
representative of what happens in human pancreatic cancer.
Cellular stress modulates WSB1 alternative splicing in
favor of isoform 3
Our hypothesis is that some of the genes over-expressed in
tumors are activated in response to the stress caused by the new
tissue microenvironment. In our experimental model, the
environment of pancreatic cancer cells is indeed quite different
when they are cultivated in vitro or growing in the nude mouse, in
terms of nutrients, growth matrix, hormones, etc. Yet, some of
these changes might be important enough to influence gene
expression but not to the point of inducing stress. To check
whether the observed changes in WSB1 gene expression are
indeed a consequence of stress, we monitored the expressoin of
WSB1 mRNA isoforms in Mia-Paca2 cells, in response to the
stress generated by various treatments. These treatments affecting
different pathways should also provide information on the function
of WSB1. They included the induction of apoptosis with
staurosporine, or adriamycine and gemcitabine which block
DNA synthesis, DNA damage by c-irradiation, metabolic stress
by serum starvation and hypoxia or anoxia. As shown in Figure 2,
all treatments resulted in a very modest change in the expression of
WSB1 isoforms 1+2 and in a strong increase in isoform 3
expression. Therefore, WSB1 isoform 3 expression seems to be
enhanced in response to stress, whatever the stress pathway
involved. Although we cannot rule out that this is in part
influenced by the presence of stroma in tumors, these results
suggest that the changes in alternative splicing observed for WSB1
in our xenograft model are indeed modulated by cell stress. Similar
results were obtained with Panc1 cells (data not shown).
Figure 2. Splicing is in favor of isoform 3 in mice xenografts, human pancreatic tumors and after stress. Expression of WSB1 isoforms
1+2 and 3 mRNAs was assessed by qRT-PCR in pancreatic cancer cell lines and in mice xenografted tumors (A), in human pancreatic cancer samples
(B), and in Mia-PaCa2 cells after treatment with stress-inducing agents (C). Values are expressed as the mean6S.D. of combined results from two
independent experiments performed in triplicate. (*, p,0.05).
doi:10.1371/journal.pone.0002475.g002
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To analyze the subcellular localization of WSB1 isoforms 1, 2
and 3 we subcloned the 3 cDNAs into the pEGFP-N1 vector to
obtain WSB1 isoforms as EGFP-WSB1 fusion proteins. These
plasmids were transfected into HeLa cells and after 24 h, isoforms
1, 2 and 3 appeared as cytoplasmic dots. No differences in dot size
or number were found between the three isoforms. EGFP-WSB1
fusion proteins may acquire abnormal spatial conformations
preventing them to reach the normal location of the protein and
possibly inducing aggregate formation which could account for
our observations. As a control, we subcloned the WSB1 isoforms
into pcDNA4 to produce three WSB1-V5 tagged proteins.
Plasmids were transfected into HeLa cells and anti-V5 antibodies
used to detect 24 h later the isoforms by immunocytochemistry.
Interestingly, the subcellular distribution of the V5-tagged isoforms
was very similar to that observed for EGFP-WSB1 isoforms
(Figure 1).
WSB1 enhances cell proliferation
Little is known about WSB1 function. WSB1, also known as
SWIP1, was first identified by Vasiliauskas et al. [10] by searching
human sequences similar to that of the chicken gene swip1. WSB1
shares 88% amino acid identity with the chicken swip1. The
authors showed that swip1 was regulated by sonic hedgehog in
somites and limb buds in the developing chicken. More recently,
Dentice et al. [11] presented evidence that WSB1 is part of an E3
ubiquitin ligase for thyroid hormone-activating iodothyronine
deiodinase-2. It is important to note that all previous experiments
have been carried out in chicken where only two isoforms,
corresponding to human isoforms 1 and 2 have been identified.
Therefore, the function of this gene in human cancer, particularly
of its isoform 3, is completely unknown. We first investigated the
role of WSB1 on cell proliferation. To this end, we inhibited
WSB1 expression by transfecting Mia-Paca2 with a siRNA that
targets the 3 isoforms. As shown in Figure 3, 48 h after
Figure 3. WSB1 enhances cell proliferation. A. Mia-PaCa2 cells were transfected with a siRNA directed against WSB1 mRNA and expression of
WSB1 isoforms 1+2+3, 1+2 and 3 mRNAs was analyzed by qRT-PCR. B. Mia-PaCa2 cells were transfected with the WSB1 siRNA and growth was
analyzed by direct cell counting (B), MTT analysis (C) or by BrdU incorporation (D) as described in Material and Methods section. E. Mia-PaCa2 cells
were transfected with the WSB1 siRNA and caspase 3 activity was measured in untreated and after treatment with staurosporine or doxorubicin.
Values are expressed as the mean6S.D. of combined results from two independent experiments performed in triplicate. (*, p,0.05).
doi:10.1371/journal.pone.0002475.g003
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sion by 85% (80% for isoforms 1+2 and 89% for isoform 3). Cell
growth was measured every 24 h, starting 48 h after siRNA
transfection, by direct cell counting and by MTT assay. In both
cases, results indicate that cells transfected with WSB1 siRNA
grew more slowly than cells transfected with the control siRNA
(Figure 3). Similar results were obtained with Panc1 cells (data not
shown). BrdU incorporation experiments confirmed these results.
However, that difference could be due to an increase in cell death
rather than to a decreased proliferation of WSB1 siRNA-
transfected cells. To test this hypothesis, we assessed apoptosis
by measuring caspase-3 activity in cells transfected with these
siRNA. Caspase-3 activity was the same in cells transfected with
WSB1 siRNA or with control siRNA. Moreover, when apoptosis
was induced by treatments with staurosporine or doxorubicin, cells
transfected with WSB1 siRNA showed a lower caspase-3 activity
than control cells (Figure 3). Taken together, these results strongly
suggest that WSB1 expression enhances cell growth by increasing
cell proliferation rather than by decreasing cell death.
A specific role for isoform 3
Expression of WSB1 isoform 3 is induced in human pancreatic
cancer cells both in vitro after exposure to a stress and in vivo
when these cells grow as xenografts in mice. It is also largely
predominant in human pancreatic tumors, suggesting that the 3
isoforms have different functions. To characterize these functions
we generated stable cell lines expressing each isoform of WSB1
separately as WSB1-EGFP fusion proteins, by transducing Mia-
PaCa2 cells with retrovirus encoding WSB1 isoforms 1, 2 or 3.
Expression of fusion proteins was evidenced by western blot
(Figure S2). We measured cell growth by direct counting each 24 h
during 4 days and found that cells expressing isoform 1 or 2 grew
more rapidly than control cells expressing EGFP alone. However,
to our surprise, cells expressing isoform 3 grew more slowly than
cells expressing isoforms 1 or 2, or control cells (Figure 3). As
previously, we ruled out that this was due to increased cell death
because caspase-3 activity was the same in the 3 cell lines (data not
shown). In addition cell cycle analysis confirmed these observa-
tions. In fact, we found the S/G1 phase ratio higher in cells
expressing isoforms 1 or 2 than in control cells, and slower in cells
expressing isoform 3 (Figure 4). Therefore, WSB1 isoforms 1 or 2
and isoform 3 have opposite effects on cell proliferation, isoform 3
inhibiting pancreatic cell growth whereas isoforms 1 and 2
stimulate their proliferation.
WSB1 isoform 3 reduces susceptibility to stress-induced
cell death
Since expression of isoform 3 is induced by stress, we
investigated whether it could affect the susceptibility of the cells
to stress-induced cell death. We submitted Mia-Paca2 cells
expressing isoforms 1, 2 or 3 to treatment with 100 or 150 mM
doxorubicin known to induce apoptosis, and measured cell
viability after 6 h. We observed with both drug concentrations
increased cell death in cells expressing isoforms 1 or 2, compared
to control cells. On the contrary, cells expressing isoform 3 were
significantly more resistant than controls (Figure 5). To check these
findings, cells were treated for 48 h with 150 and 350 mM
gemcitabine and cell viability was assessed. A profile similar to that
of doxorubicin-treated cells was obtained, cells expressing isoforms
1 and 2 being more sensitive to the drug than control cells,
contrary to cells expressing isoform 3 (Figure 5). These drugs kill
dividing but not arrested cells, but the differences after 6 hour of
treatment are too important to be totally explained by the fact that
slower growing cells die more slowly. These results show that over-
expression of WSB1 isoform 3 and down-regulation of isoforms 1
and 2 in response to cellular stress results in increased resistance to
apoptosis.
Discussion
The hypothesis supporting this work is that pancreatic tumor
progression and metastasis occurs only when circulating cancer
cells can successfully resist the stresses generated by the new
microenvironment provided by the host tissue. If escaped cancer
cells were not submitted to stress in new environments, metastasis
would develop in all tissues. In fact, clinical observation is that
primary cancers developing in a given organ always develop
metastases in the same other organs, probably the ones in which
these cancer cells are able to resist the stress caused by the
environmental conditions. Consequently, therapeutic strategies
that interfere with the mechanisms protecting cancer cells from
stress might slow down or prevent the metastatic process. The first
step towards establishing such strategies is to identify the genes that
confer resistance to the new microenvironment during tumor
development. This can be achieved by comparing by DNA array
gene expression in cells growing in different microenvironmental
conditions, then select the genes overexpressed in conditions of
tumor growth. To mimic the stress that occurs during metastasis
formation in patients, we used an experimental set-up based on a
xenograft pancreatic tumor model. We compared the gene
expression profiles of human pancreatic cancer cell lines growing
in vitro under standard culture conditions (microenvironment A)
and during tumor development after injection into nude mice
(microenvironment B). Indeed, many genes showed overexpres-
sion in the new microenvironment and if some of them might be
overexpressed in response to the signals like cell-to-cell or cell-to-
extracellular matrix contact, others might be implicated in
resistance to stress. We selected as best candidates the genes
strongly overexpressed in the xenografts generated by all 5 cell
lines. Among candidate genes, we chose to characterize in detail
WSB1 because it presented the further interest of generating by
alternative splicing three distinct isoforms whose regulation upon
exposure to stress is not coordinated. Although over-expression of
isoforms 1+2+3 is moderate, 1.75 to 3.93 fold depending of the cell
type, isoform 3 is strongly over-expressed (3.7 to 9 fold). On the
contrary, expression of isoforms 1+2 is decreased to 5 to 20% in
xenografts. Interestingly, isoform 3 is also largely predominant in
human pancreatic tumors, which supports our working hypothesis.
Although the U133A genechip has been designed to target
human sequences, we cannot rule out a potential cross-
hybridization of some probes with mouse sequences. This is why
designed Homo sapiens-specific primers for qPCR. qPCR were
performed on mouse embryonic fibroblasts cDNA in the same
conditions as for human pancreatic cDNA and there was no DNA
amplification after 45 cycles, although we were able to amplify the
entire isoform 3 from the same mouse embryonic fibroblasts
cDNA by a PCR with primers matching perfectly sequences
common to both species (Forward 59-CCATGAGC-
CAGCTTTCCC-39; Reverse 59-TCACACCAATATTGCTGC-
CAC-39). Therefore, we concluded that our qPCR primers are
human-specific and that the enhanced expression of isoform 3
occurs in human epithelial cells and not in mouse stroma.
To validate that WSB1 is indeed a stress-induced gene, we
submitted pancreatic cells to several stresses and observed that
expression of WSB1 isoform 3 was always strongly activated
whereas expression of isoforms 1+2 was unchanged or decreased.
That cellular stress regulates WSB1 expression by modulating its
splicing is indeed interesting but not original since such regulation
WSB1 in Pancreatic Cancer
PLoS ONE | www.plosone.org 5 June 2008 | Volume 3 | Issue 6 | e2475Figure 5. WSB1 isoform 3 reduces susceptibility to stress-induced cell death. Mia-PaCa2 cells were transduced with retrovirus expressing
WSB1 isoforms 1, 2 or 3 as EGFP fusion protein or EGFP as control and selected with puromycin. Cells were treated with gemcitabine (100 and
150 mM) for 48 hours or with doxorubicin (150 and 350 mM) for 6 hours. Cell viability was measured by MTT. Values are expressed as the mean6S.D.
of combined results from two independent experiments performed in triplicate. (*, p,0.05).
doi:10.1371/journal.pone.0002475.g005
Figure 4. A specific role for isoform 3 which reduces pancreatic cancer cell growth. A. Mia-PaCa2 cells were transduced with retrovirus
expressing WSB1 isoforms 1, 2 or 3 as EGFP fusion protein or EGFP alone as a control and selected with puromycin. Cell growth was measured by
direct counting after plating 10
5 cells in 48-well dishes every day during 4 days. B. After synchronization with 24 h serum-starvation, cells were
incubated in serum containing medium for 24 h, stained with propidium iodide and cell cycle was analysed with a flow cytometer. C. S/G1 ratio.
Values are expressed as the mean6S.D. of combined results from two independent experiments performed in triplicate (A) or trice in triplicate (B and
C) (*, p,0.05).
doi:10.1371/journal.pone.0002475.g004
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of alternative splicing occur for Arabidopsis SR protein homo-
logues, atSR30 and atSR45a, in response to environmental stress
[12]. Also, UV and c radiation as well as cisplatin treatment
induce alternative splicing of hdm2 [13] and exposure of primary
lymphocytes to a stress induces the appearance of TSG101
splicing variants [14]. Finally, in neurons, acetylcholinesterase
shifts from isoform AChE-S to the normally rare isoform AChE-R
in response to several stresses [15]. The important point is that
stress-induced modulation by alternative splicing of the expression
of WSB1 isoforms is very similar to what we observed during
xenograft tumor progression.
It is noteworthy that human WSB1 isoform 3 sequence has
been permanently suppressed from databases for being a
nonsense-mediated mRNA decay (NMD) candidate. NMD is
an mRNA surveillance pathway that ensures the rapid
degradation of mRNAs containing premature translation termi-
nation codons, thereby preventing the accumulation of truncated
and potentially harmful proteins [16]. In this study, we show an
accumulation of isoform 3 mRNA after stress induction, in
xenograft and in human pancreatic tumors contrary to what
would be expected in a NMD context. Therefore, although its
sequence could be related to NMD, it is obvious that WSB1
isoform 3 mRNA is not rapidly degraded and does not seem to
be a real target for NMD. We also ruled out by RT-PCR
amplification and sequencing the entire isoform 3 mRNA the
fact that a pre-mRNA is detected instead of isoform 3 mRNA
(data not shown).
The physiological consequences for pancreatic cancer cells of
stress-induced changes in the proportions of WSB1 isoforms, in
terms of growth rate and resistance to apoptosis, are important.
Expression of WSB1 isoforms 1 or 2 was shown to accelerate cell
cycle whereas expression of isoform 3, on the contrary, slowed it
down. When all isoforms were concomitantly targeted by a
siRNA in Mia-PaCa2 or Panc1 cells growth was significantly
reduced, which was expected because isoforms 1 and 2 are
abundant in non-stressed cells that show normal growth. Hence,
in stress conditions growth is limited both by the decreased
expression of isoforms 1 and 2 and by the overexpression of
isoform 3. On the other hand, expression of isoform 1 or 2
increases the sensitivity of cells to pro-apototic stimuli whereas
expression of isoform 3 increases their resistance. Again, the
stress-induced inhibition of isoforms 1 and 2 expression and
overexpression of isoform 3 both help the cells coping with a
different environment. The molecular mechanisms by which
these proteins can affect cell growth and resistance to apoptosis
in opposite directions remain to be determined, although the loss
in isoform 3 of the C-terminal part of isoform 1 should probably
account for part of it. Yet, in spite of important structural
differences, the 3 WSB1 isoforms are similarly distributed in the
cytoplasm as shown in Figure 1.
In conclusion, we report that the shift in WSB1 isoform
expression observed in human pancreatic cancer cells submitted
to a stress is similar to the shift observed when these cells are
xenografted in nude mice or in human pancreatic tumors. If
that shift results in decreased growth rate of the cells, it also
increases significantly their resistance to apoptosis. These data
support the hypothesis that activation of stress-response
mechanisms helps cancer cells establishing metastases, inasmuch
as the same WSB1 isoform ratio is observed in pancreatic
adenocarcinomas. Whether the stress-induced changes in WSB1
isoform expression is necessary for tumor development, which
would make it a potential therapeutic target, remains however
to be investigated.
Materials and Methods
Cell lines and cell culture conditions
The human pancreatic cancer-derived Mia-PaCa2, BxPC3,
Panc-1, Capan-1 and Capan-2, and the Phoenix Amphotropic
viral packaging cell lines were cultivated as recommended by
American Type Culture Collection.
Subcutaneous tumor induction in nude mice
Suspensions of pancreatic cell lines, (10
7/200 ml PBS) were
injected subcutaneously into the flank of male athymic 7–8 week-
old nude mice, and tumors were allowed to develop for 30 days.
All studies were performed in accordance with the European
Union regulations for animal experiments.
Human pancreatic tumor samples
Pancreatic tissue was obtained from patients that underwent
pancreatic resection at the Department of Surgery, Hopital Nord,
Marseille, France. Institutional Review Board approval was
obtained from the Comite ´ d’Ethique de l’Institut Paoli Calmettes
(Marseille, France). Written informed consent was obtained from
the patients in accordance with the Helsinki Declaration.
RNA isolation
Total RNA was isolated by the Trizol (Gibco-BRL) procedure.
Microarray
The experiment was performed on U133 2.0 Plus Genechip
(Affymetrix, Santa Clara, CA), as previously described[17] , and
analyzed with the Microarray Suite 5.0 software (Affymetrix).
Treatments
In some experiments, Mia-Paca2 cells were treated during 24 h
with 10 mM Doxorubicin (Sigma), 0.5 mM Staurosporine (Sigma)
or 350 mM Gemcitabine (Eli Lilly) or submitted to 24 h serum
deprivation, or to c-irradiation (5Grays).
Hypoxia/Anoxia
Oxygen concentrations were modified using an hypoxia
incubator chamber (catalogue # 27310; Stem Cell Technologies)
and appropriate gas mixtures (Linde gas, France), following the
instructions of the manufacturer. Cells were submitted to 5 h
anoxia (5%CO2, 95% N2) or to 6–18 h hypoxia (5%CO2, 94.8%
N2 and 0.2%O2).
Quantitative RT-PCR analysis
First-strand cDNA was synthesized using Expand Reverse
Transcriptase (Roche, Meylan, France). Quantitative PCR was
performed using Roche Light Cycler system and reagents,
following instructions of the manufacturer. Primers used and
conditions of annealing were 59-AGTGTCAGACTGATCTGG-
39 and 59-ACAGTAGACGGATTCTTCAA-39,5 8 uC for 7 sec;
59-GATCATACTGAAGTGGTCAG-39 and 59-GCCCAAAT-
TCCATCAGAATG-39,5 6 uC for 14 sec; and 59-GATCGTGGT-
TAGTTTGGG-39 and 59-TGGGTCACCAACTTGAG-39,
57uC for 6 sec ; for global expression of wsb1, isoforms 1+2 and
isoform 3 respectively. (see Supplementary Figure S1) Each sample
was analyzed in duplicate and the experiment was repeated twice.
Results were analyzed using RelQuant (Roche) and expressed as a
ratio of Tata box Binding Protein (TBP) or of control values
(untreated cells).
WSB1 in Pancreatic Cancer
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Cells were transfected using FuGENE HD (Roche Diagnostics)
following the manufacturer’s instructions with the pEGFP-N1
plasmid (Clontech) containing full-length human WSB1 cDNA,
isoform 1, 2 or 3 (respectively NM_015626, NM_134265,
NM_134264), or no insert. The 3 isoforms were also subcloned
in the pcDNA4-V5-A plasmid (Invitrogen).
WSB1 fluorescence
The mouse anti-V5 antibody (InVitrogen) was used to detect
V5-tagged WSB1 proteins, and revealed by the goat chromeo 488-
conjugated anti-mouse secondary antibody (ActiveMotif). Cells
expressing the EGFP-WSB1 fusion proteins were only fixed. Cells
were mounted in ProLong Gold (Invitrogen) and analyzed with a
Nikon I90 microscope (406/APO plan/NA1.40).
Retroviral vector and retroviral-mediated gene transfer
The 3 isoforms of WSB1 fused to EGFP, or EGFP alone, were
subcloned into the pLPCX retroviral vector obtained from S.
Lowe (Cold Spring Harbor Laboratory, NY). Phoenix Ampho-
tropic packaging cells were transfected with polyethyleneimine
with 5 mg of retroviral plasmid. Forty-eight hours later, the
supernatant was supplemented with 4 g/ml polybrene (Sigma) and
added to the culture medium (v/v) of Mia-PaCa2 cells. The
population of WSB1-EGFP-expressing cells was selected with
1 mg/ml puromycin. Mia-PaCa2 cells infected with the EGFP
expressing vector were used as control.
siRNA-mediated knock-down of WSB1 expression
WSB1 expression was knocked-down in cultured cells with a
specific siRNA. Mia-PaCa2 cells were transfected using Xtrem-
gene reagent (Roche Diagnostics), following the manufacturer’s
instructions, with a siRNA designed for WSB1 mRNA (sense 59-
GAAAACUCCUCCUUAACUUd(TT)-39) (Dharmacon) or con-
trol siRNA, (sense 59-UUCUCCGAACGUGUCACGUd(TT)-39)
(Qiagen).
MTT/cell viability assays
Every day after siRNA transfection, cells were incubated with
0.5 mg/ml MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetra-
zolium bromide; Sigma) for 2 h at 37uC and 5% CO2. The
reaction was stopped, and formazan crystals were dissolved in a
0.1N HCl-isopropanol solution. MTT metabolism (at an optical
density of 570 nm [OD570]) was read and normalized to cell
density (OD690). Assays were performed thrice and in triplicate.
Alternatively, cell viability was determined by direct counting via
trypan blue exclusion. The number of viable cells after treatment
with gemcitabine during 48 h or doxorubicin during 6 h was
determined by the trypan blue dye exclusion test.
BrdU proliferation assays
Cell proliferation was measured using 5-Bromo-29-deoxy-
uridine Labeling and Detection Kit III (Roche Diagnostics)
according to the instructions of the manufacturer, after 16 h
incubation with BrdU. Results were normalized for cell viability
(MTT).
Caspase 3/7 activity
Caspase activity was measured in Mia-PaCa2 cells by using the
Apo-ONE Homogeneous Caspase 3/7 Assay Fluorometric Kit
(Promega), and performed as recommended by the manufacturer,
48 hours after transfection with WSB1 or control siRNA. Results
were normalized for cell viability (MTT).
Cell cycle analysis
Cells were synchronized by 24 h serum-starvation and collected
after 24 h incubation in serum-containing DMEM. Then, cells
were washed with PBS and fixed in cold-ethanol 70% for
30 minutes at 4uC. After a wash with PBS, cells were treated
with 50 mL RNase A (100 mg/mL), labeled with 250 mL
propidium iodide (50 mg/mL), and immediately analyzed by flow
cytometry (FACSCalibur, Becton Dickinson, Le Pont-De-Claix,
France). Cell cycle analysis was done on 25,000 cells, evaluating
the G1, S and G2 phases (FlowJo 7.2.2). The experiments were
repeated thrice and each sample was assayed in triplicate.
Statistical analysis
Statistical analysis was performed by ANOVA with post hoc
analysis Student-Neuman-Keuls test. Results shown represent
mean6S.D.
Supporting Information
Figure S1 Schematic representation of each isoform mRNA and
location of the primers used for qPCR.
Found at: doi:10.1371/journal.pone.0002475.s001 (0.50 MB TIF)
Figure S2 WSB1 expression in stable cell lines. Expression of
each transfected WSB1 isoform as EGFP fusion protein was
evidenced by western blot, using an anti-EGFP antibody.
Found at: doi:10.1371/journal.pone.0002475.s002 (0.14 MB TIF)
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